43 results on '"Fermé, Christophe"'
Search Results
2. Challenges and perspectives in the immunotherapy of Hodgkin lymphoma
3. ABVD or BEACOPPbaseline along with involved-field radiotherapy in early-stage Hodgkin Lymphoma with risk factors: Results of the European Organisation for Research and Treatment of Cancer (EORTC)–Groupe d'Étude des Lymphomes de l'Adulte (GELA) H9-U intergroup randomised trial
4. Combination of ofatumumab and reduced-dose CHOP for diffuse large B-cell lymphomas in patients aged 80 years or older: an open-label, multicentre, single-arm, phase 2 trial from the LYSA group
5. Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High-Dose Therapy with Stem Cell Transplantation in Poor-Risk Patients with Diffuse Large B Cell Lymphoma
6. Role of FDG-PET in the Implementation of Involved-Node Radiation Therapy for Hodgkin Lymphoma Patients
7. Cytokine gene polymorphisms and progression-free survival in classical Hodgkin lymphoma by EBV status: Results from two independent cohorts
8. Dose-dense rituximab-CHOP compared with standard rituximab-CHOP in elderly patients with diffuse large B-cell lymphoma (the LNH03-6B study): a randomised phase 3 trial
9. Low-Dose Radiation Treatment in Pulmonary Mucosa-Associated Lymphoid Tissue Lymphoma: A Plausible Approach? A Single-Institution Experience in 10 Patients
10. Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
11. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial
12. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte
13. Quality of life after successful treatment of early-stage Hodgkin's lymphoma: 10-year follow-up of the EORTC–GELA H8 randomised controlled trial
14. Rituximab combined with chemotherapy and interferon in follicular lymphoma patients: results of the GELA-GOELAMS FL2000 study
15. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: Whole-body MRI, PET/CT and bone marrow biopsy
16. Long-term results and competing risk analysis of the H89 trial in patients with advanced-stage Hodgkin lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte (GELA)
17. Phase II study of concomitant chemoradiotherapy in bulky refractory or chemoresistant relapsed lymphomas
18. Rituximab maintenance obviates the poor prognosis associated with circulating lymphoma cells in patients with follicular lymphoma
19. Randomized Phase III Study Comparing an Early PET Driven Treatment De-Escalation to a Not PET-Monitored Strategy in Patients with Advanced Stages Hodgkin Lymphoma: Interim Analysis of the AHL2011 Lysa Study
20. Impact of Rituximab-Based Immunochemotherapy Induction and Maintenance on the Immunisation Rate Against Tetanus Toxin in Follicular Lymphoma Treated Patients : A Subanalysis of the PRIMA Study
21. Pre-Phase Chemotherapy Followed By Ofatumumab (OFA) and Reduced Dose CHOP (OFA-mini-CHOP) for Patients over 80 Years with Diffuse Large B-Cell Lymphoma (DLBCL) – a Lymphoma Study Association (LYSA) Prospective Phase II Study (LNH09-7B)
22. Management and Outcomes of Nodular Lymphocyte Predominant Hodgkin Lymphoma: A Retrospective Study By the Lymphoma Study Association
23. A Phase III Randomized, Double Blind, Placebo Controlled Multi-Center Study Of Panobinostat For Maintenance Of Response In Patients With Hodgkin Lymphoma Who Are At Risk For Relapse After High Dose Chemotherapy and Autologous Stem Cell Transplant: Final Results After Early Trial Discontinuation
24. Upfront Consolidation Combining Yttrium-90 Ibritumomab Tiuxetan and High Dose Therapy with Stem-Cell Transplantation in Poor Risk Patients with Diffuse Large B-Cell Lymphoma
25. Interim Analysis of the Randomized Eortc/Lysa/Fil Intergroup H10 Trial On Early PET-Scan Driven Treatment Adaptation in Stage I/II Hodgkin Lymphoma
26. Long-Term Prognostic Significance of Response in Hodgkin Lymphoma Before Autologous Stem Cell Transplantation :Results of the Prospective Multicenter H96 Trial by the GELA/SFGM-TC Study Group
27. R-ACVBP Benefits to Younger Patients with Non-Germinal Centre Diffuse Large B-Cell Lymphoma As Compared to R-CHOP in the GELA Trial LNH03-2B
28. First Report On the H10 EORTC/GELA/IIL Randomized Intergroup Trial On Early FDG-PET Scan Guided Treatment Adaptation Versus Standard Combined Modality Treatment in Patients with Supra-Diaphragmatic Stage I/II Hodgkin's Lymphoma, for the Groupe d'Etude Des Lymphomes De l'Adulte (GELA), European Organisation for the Research and Treatment of Cancer (EORTC) Lymphoma Group and the Intergruppo Italiano Linfomi (IIL).
29. Tandem Autologous/Allogeneic Stem Cell Transplantation for Multiple myeloma: Long-Term Outcome of a Retrospective Study
30. High-Dose Methotrexate and Cytarabine Chemotherapy May Be Effective and Safe in Solid Organ Transplant Recipients with Primary CNS Lymphomas (PCNSL)
31. Prognostic Value of Angiogenic Factors (Vacular Endothelial Growth Factor [VEGF] and Basic Fibroblast Growth Factor [bFGF]) and Endostatin in Patients with Non-Hodgkin Lymphoma.
32. Plitidepsin Is Active in Peripheral T-Cell Lymphoma (PTCL): A Subset Analysis from An Ongoing Multicenter Phase II Trial.
33. Survival Impact of Rituximab Combined to ACVBP (R-ACVBP) in 209 Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Upfront High-Dose Consolidative Autotransplantation (HDC) : A GELA Phase II Study
34. Cytokine Gene Polymorphisms and Outcome of Patients with Hodgkin Lymphoma: A Prospective Study of the Groupe D'Etude Des Lymphomes De L'Adulte
35. Rituximab Combined with Chemotherapy and Interferon in Follicular Lymphoma Patients: Final Analysis of the GELA-GOELAMS FL2000 Study with a 5-Year Follow-Up.
36. A Multicenter Study of a Gemcitabine-Based Regimen in Relapsed or Refractory Hodgkin's Lymphoma Patients.
37. Rituximab Combined to ACVBP (R-ACVBP) as a New Inductive Treatment Followed by High-Dose Consolidative Autotransplantation (HDC) for Poor Risk Diffuse Large B-Cell Lymphoma (DLBCL) in First-Line. Preliminary Results on 119 Patients of a GELA Phase II Study.
38. Single or Tandem Autologous Stem-Cell Transplantation Given According to Prognostic Factors at Relapse for Hodgkin Lymphoma.
39. Four ABVD and Involved-Field Radiotherapy in Unfavorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin's Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-U Trial.
40. Rituximab vs Observation after High-Dose Consolidative First-Line Chemotherapy (HDC) with Autologous Stem Cell Transplantation in Poor Risk Diffuse Large B-Cell Lymphoma. Final Analysis of the LNH98-B3 GELA Study.
41. ALK is not expressed in Hodgkin disease
42. Combined chemotherapy-radiotherapy in advanced Hodgkin's disease: Results of a prospective clinical trial with 70 stage IIIB-IV patients
43. Treatment-Related Deaths and Second Cancer Risk After Autologous Stem-Cell Transplantation for Hodgkin's Disease
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.